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Abstract 
Importance:  Merkel cell carcinoma (MCC) is an uncommon but highly invasive form of 
skin cancer.  The mechanisms that cause MCC are yet to be fully determined.   
Objective:  To examine the incidence and survival of MCC within a population known to be 
at high risk of other skin cancers.  
Design:  Retrospective cohort study. 
Setting:  Population-based administrative data for MCC collected by the Queensland Cancer 
Registry, supplemented with detailed histopathological data.   
Participants:  De-identified records were obtained of all Queensland residents diagnosed 
with MCC during the period from 1993 to 2010.  A sub-sample of histopathology records 
were reviewed by a senior dermatopathologist to determine the potential for misclassification.  
A total of 879 eligible cases of MCC were included in the study.      
Main Outcomes and Measures:  Incidence rates were directly age-standardised to the 2000 
United States Standard Population.  Trends were examined using JoinPoint software with 
results expressed in terms of the annual percentage change.  The period method was used to 
calculate five-year relative survival and adjusted hazard ratios were obtained from 
multivariate Poisson models. 
Results:  There were 340 cases of MCC diagnosed in Queensland between 2006 and 2010, 
corresponding to an incidence rate of 1.6/100,000 population. Males (2.5/100,000) had higher 
incidence than females (0.9/100,000) and rates peaked at 20.7/100,000 for persons aged 80 
years and over. The overall incidence of MCC increased by an average of 2.6% per year from 
1993 onwards. Relative survival was 41% after 5 years, with significantly better survival 
found for those aged under 70 years old at diagnosis (between 56-60%), tumours on the 
face/ears (51%) and stage I lesions (49%).       
Conclusions and Relevance:  Incidence rates for MCC in Queensland are at least double any 
that have been previously published elsewhere in the world.  Our findings indicate that a 
correlation exists between ambient levels of ultraviolet radiation and the incidence of MCC.       
 
     
Introduction 
Merkel cell carcinoma (MCC) is a rare and highly invasive form of neuroendocrine skin 
cancer that was first described by Toker
1
 as trabecular carcinoma in 1972.  The neoplasms are 
composed of small, round blue cells sharing histomorphological and immunohistochemical 
features with various neuroectodermally derived cells including cutaneous Merkel cells.
2,3
  It 
is currently unclear whether MCCs actually derive from cutaneous Merkel cells or whether 
they share a common precursor.
2,4,5
    
 
MCCs can be difficult for clinicians to identify because of their nondescript features.
6
  
However, just recently Jalilian and colleagues
7
 described that the four most frequent clinical 
features were cherry red colour, shiny surface, sharp circumscription and nodular 
morphology.  They also outlined significant dermoscopic features including linear irregular 
and polymorphous vessels, poorly focused vessels and milky pink areas.
7
  Despite the rather 
characteristic histopathological features, immunohistochemistry staining is required for a 
definitive diagnosis to differentiate MCC from a broad spectrum of small, round, blue cell 
neoplasms (e.g. metastasis of an oat cell carcinoma of the lung).
2,5,8
  The tumours typically 
have rapid growth, meaning many patients develop metastatic disease, and recurrence is 
common despite surgical removal of the primary lesion.
2,8
   
 
MCC is most often diagnosed among elderly Caucasians, with the majority of cases occurring 
on parts of the body that are more likely to be exposed to the sun, such as the head and 
neck.
2,5,8
  Immunosuppression, which occurs when the body's normal immune responses are 
inhibited due to medical intervention or disease, is another recognised risk factor,
2,5
 and is 
suggestive of a viral aetiology.
8
  The discovery of a polyomavirus (MCPyV)
9
 that is present 
in the majority of MCC tumours has offered new insights into its pathogenesis,
8,10,11
 although 
much remains unknown.  For example, while there is an established association between 
MCC and ultraviolet (UV) radiation,
8
 it is not clear whether UV radiation contributes directly 
to the development of MCC or if it acts in combination with immunosuppression.
10
   
 
The state of Queensland located in north-eastern Australia has a sub-tropical climate with 
high levels of UV radiation all year round, combined with a predominantly fair-skinned 
population and an outdoors lifestyle.  Queensland consequently has the highest reported 
incidence rate of skin cancers worldwide, particularly invasive melanoma.
12-14
  The main aim 
of this paper was to compare the incidence of MCC in Queensland to elsewhere in the world.  
We also examined incidence trends and investigated differences in survival by key 






Approval for this study was granted by the Griffith University Human Research Ethics 
Committee (PBH/34/11/HREC).   Population-based data on all cases of MCC (defined as 
ICD-O code C44 and morphology code M8247-3) diagnosed for residents of Queensland 
between 1993 and 2010 inclusive were obtained from the Queensland Cancer Registry.  We 
excluded cases that were diagnosed prior to 1993 due to the possibility of underreporting of 
MCC in this period.
15
  MCCs were further restricted to those occurring on the skin. 
 
The data available from the Queensland Cancer Registry included demographic information 
(sex, age at diagnosis, remoteness of residence), diagnostic details (year and anatomical site), 
full history of any other cancer diagnoses, and, where relevant, items relating to mortality 
(time from diagnosis to death and cause of death).  Additional clinical information was 
extracted from histopathology reports where available, including the size of the lesion, lymph 
node involvement, recurrence, metastases and immunohistochemistry results.  
Immunosuppression status was categorised as “known to be immunosuppressed” for persons 
who were a transplant recipient, were HIV positive or who were reported to have another 
cause of immune suppression. Cases were staged according to the criteria set out by the 




A positive test for cytokeratin 20 (CK20) was considered as confirmation of a diagnosis of 
MCC, but other variants exist that are CK20 negative.
4,17
  To estimate the potential for 
misclassification of cases that were included in the study, a subsample of approximately 1 in 
10 of the histopathology reports for tumours coded to MCC where a negative result was 
returned for CK20 or where CK20 testing was not recorded were reviewed by a senior 
dermatopathologist (HPS).   
 
Statistical analyses 
Annual incidence rates for the period 1993-2010 and average incidence rates for the latest 5-
years (2006-2010) were generated by sex, age group, site and stage at diagnosis.  Estimated 
resident population information used for the rate denominators was obtained from the 
Australian Bureau of Statistics.
18
 To allow for consistency with other similar studies,
15,19
 rates 
were directly age-standardised to the 2000 United States Standard Population.
20
  Incidence 
rate ratios were calculated by simple division, with confidence intervals derived using the 




Incidence trends were analysed using Joinpoint regression models (software developed by the 
National Cancer Institute, version 4.0.4).  This approach quantifies the annual percentage 
change (APC) and specifies any significant changes to the magnitude or direction of the trend 
(known as a “joinpoint”) based on Monte Carlo permutation tests.
22
  A maximum of 2 
joinpoints were specified in each model, with a minimum of 5 years allowed between 
joinpoints or between a joinpoint and either end of the data series. Two-sided t-tests were 
used to determine the statistical significance of the trends (p<0.05). 
 
Median survival time, defined as the time from diagnosis to censoring or death, was 
calculated using the reverse Kaplan-Meier method.
23
  Follow-up was censored for subjects 
who were alive at the end of the study period, as well as at the date of death for those who 
died from causes other than MCC when examining cause-specific survival.  One case was 
excluded from the survival analysis due to diagnosis on the basis of death certificate only.     
 
Five-year survival was evaluated using the period method,
24
 which follows rolling groups of 
patients within a recent “at risk” window of time and thus has the advantage of producing 
more up-to-date survival estimates than the more traditional cohort method.  In the current 
study, persons diagnosed with MCC contributed to the survival calculations if they were a 
prevalent case at some time between 1st January 2006 and 31st December 2010.  Estimates 
for both relative survival and MCC-specific survival were produced.  Relative survival was 
calculated by dividing the observed survival probability for the study group by the expected 
survival within the Queensland population,
25
 matched by age group, sex and year. The Ederer 
II technique
26
 was utilised to compute expected survival. 
 
Differences in survival were assessed by applying multivariate Poisson models to examine 
excess mortality up to 5 years after diagnosis,
27
 with results expressed in terms of adjusted 
hazard ratios.  The dependent variable was the number of deaths, with an offset term for the 
log of the person years at risk.  A range of key demographic and clinical variables were 
included in the initial model in order to determine which of these characteristics had 
independent prognostic value.  Variables were excluded if there was no evidence (p>0.25) of 
their overall effect on survival (remoteness of residence and level of invasion).  Sex, age 
group, body site, multiple primary cancers, stage at diagnosis and surgical margins were 
retained in the final model.  If the overall effect for a variable was not statistically significant 
(p≥0.05), then it was deemed that there was no difference in survival even if there appeared 
to be individual differences in the adjusted hazard ratios between some of the categories.  
 






A total of 903 cases of MCC were diagnosed in Queensland between 1993 and 2010.  Of 
these, 24 were excluded because the lesion occurred on sites other than the skin (mainly on 
the lips), leaving 879 eligible cases in our cohort.   
 
The distributions for some of the main characteristics of the cohort are given in Table 1.  
Males accounted for around two-thirds of all cases (68%), with a median age at diagnosis of 
75.5 years compared to 78 years for females.  Half of the cases were diagnosed at stage I 
while 12% already had lymph node metastases (stage III) and a further 15% had distant 
metastases (stage IV) at the time of diagnosis.  Only 1% of patients in the cohort were known 
to be immune suppressed.  More than a third (36%) were diagnosed with another primary 
cancer apart from MCC, including 10 patients (1%) with chronic lymphocytic leukaemia and 
18 patients (2%) with a lymphoma.  
 
The most common site was the face/ears (35%), although the distribution of MCC across the 
body sites differed by sex (p < 0.001).  In particular, MCCs on the face/ears occurred more 
frequently for males (38%) than females (29%), while females were far more likely to have a 
MCC diagnosed on their lower limbs compared to males (26% and 11%, respectively). 
Females also had a higher proportion of MCCs that had not yet penetrated beyond the dermal 
layers of the skin (31% compared to 23% of their male counterparts).  No statistically 
significant differences by sex were found among MCC patients by age group at diagnosis, 
remoteness of residence, presence of any multiple primary cancers (including second primary 
MCCs), stage at diagnosis, surgical margins or immunosuppression status.   
 
The average annual age-standardised incidence rate of MCCs in Queensland between 2006 
and 2010 was 1.6/100,000 population (95% CI = 1.5-1.8, Supplementary Table 1).  Incidence 
was almost 3 times higher for males (2.5/100,000) compared to females (0.9/100,000).  Rates 
increased rapidly by age, peaking at 20.7/100,000 for persons aged 80 years and over.   
 
Incidence rate trends for MCC in Queensland increased by an average of 2.6% per year (95% 
CI = +1.1%,+4.2%) between 1993 and 2010, equating to a total rise of 54% over that time 
interval (Table 2 and Figure 1).  Significant and ongoing annual increases were found for 
males (+2.5% per year), people in the older age groups (70-79 years = +2.3%; 80 years and 
over = +3.7%) and tumours that occurred on the head (+3.1%).  Significant increases were 
also observed for tumours that were either stage I (+3.6%) or stages II+ (+2.9%). 
 
Survival 
There were 281 deaths (32%) due to MCC within the study group between 1993 and 2010.  A 
further 82 people in the cohort (9%) died from other types of cancers, 213 deaths (24%) were 
from non-cancer causes, and the remaining 303 persons (34%) were still alive as at the end of 
2010.  Of the other cancer-related deaths, the main causes were other types of skin cancer and 
lung cancer (14 deaths each).  
 
The median follow-up time for cases that were prevalent between 2006 and 2010 was 2.8 
years (interquartile range = 1.2-6.1 years).  Cause-specific survival was 88% (95% CI = 84%-
91%) after 1 year and 66% (95% CI = 60%-71%) after 5 years.  The corresponding estimates 
for 1- and 5-year relative survival were 77% (95% CI = 71%-81%) and 41% (95% CI = 34%-
48%), respectively. 
 
After adjustment for confounding variables, significant differences in survival remained for 
age group, site and stage at diagnosis (Table 3 and Figure 2).  Specifically, persons who were 
aged 80 years and over were three times (adjusted HR = 3.0, 95% CI = 1.8-5.1) more likely 
to die from MCC within 5 years of diagnosis compared to those aged 60-69. Persons with an 
MCC on either the trunk (adjusted HR = 2.2, 95% CI = 1.2-4.1) or lower limbs (adjusted HR 
= 1.8, 95% CI = 1.1-3.0) had around double the risk of MCC-related mortality compared to 
MCC on the face/ears; however, there was no significant difference for lesions on the 
scalp/neck or upper limbs/shoulders in relation to the face/ears.  The risk of MCC-related 
mortality was also around double for either stage II (adjusted HR = 1.8, 95% CI = 1.1-3.2) or 
stage IV tumours (adjusted HR = 2.3, 95% CI = 1.2-4.4) compared to stage I.  No significant 
survival differences were found for sex, remoteness of residence, level of invasion, surgical 




This paper contains the first description of the epidemiology for MCC in the state of 
Queensland, Australia.  Several recent population-based studies have been published on the 
incidence of MCC.
15,19,28-31





 to 0.8/100,000 in Western Australia.
15
  Our results therefore reveal that the 
incidence rate of MCC in Queensland is at least double that previously reported anywhere 
else in the world.   
 
Queensland has a predominantly white population living in an area with high levels of 
ambient UV radiation throughout the year.
32
 The higher incidence compared to other 
countries/regions therefore appears to support a link between exposure to UV radiation and 
MCC, and is consistent with Agelli and Clegg,
33
 who noted a correlation between the UV 
index and rates of MCC in the United States.  In addition, the majority of MCCs in 
Queensland were found on sun-exposed sites such as the face and ears, scalp and neck, and 
upper limbs and shoulders, whereas in a less sunny country such as Sweden, a relatively 
larger percentage of MCCs were observed on the trunk.
29
  Our finding of a higher proportion 
of MCCs occurring on the lower limbs among females is similar to the site distribution of 
melanoma,
34
 another cancer that is strongly related to sun exposure.  Similar to Western 
Australia
15
, which also has a high UV index, we found that MCCs occurred more frequently 
for males than females. This contrasts with what has been reported in several places in 
Europe.
28-31
   
 
Average age at diagnosis in other studies ranged from 75-78 years, consistent with the 
median of 76 years of age in the Queensland cohort.    However, a higher proportion (15%) of 





There was an annual increase of 8% in the incidence of MCC in the United States between 
1986-2001,
35
 while rates doubled in the Netherlands between 1993-2007
30
.  Although the 
magnitude of the increase in both of these countries has been considerably greater than that 
observed in Queensland, their incidence rates still remain much lower.  The incidence of 
MCC has stayed fairly stable in Nordic countries since the mid-1990s.
31
  At least part of the 
rapidly increasing incidence rates in the United States during the last two to three decades has 
been attributed to advances in diagnostic techniques, such as immunohistochemistry, along 
with greater awareness on the part of medical practitioners.
4,19
  This means that a larger 
proportion of MCC cases are now correctly identified.  Changes in the proportion of the 
population who are immunosuppressed could also have contributed.
30
  It is unknown to what 
extent these factors may have influenced incidence rate trends in Australia, and also why 
there has been no subsequent change in incidence rates of MCC in countries such as Finland, 




Although the incidence rate of MCC is about forty times lower than invasive melanoma in 
Queensland,
38
 these two types of skin cancers share some epidemiological characteristics. For 
example, they are more common among males and the elderly.  The incidence of both is 
continuing to increase sharply among older people, while rates have stabilized among those 
who are younger.
13
 If the role of UV radiation in the development of MCC is found to be 
similar to that of melanoma, then this stabilising of rates among younger people may provide 
support for the effectiveness of prevention campaigns.
34
   
 
An analysis of data from Finland reported a similar estimate to ours for 5-year relative 
survival among males (36%), but a much higher rate for women (69%).
31
  Lemos et al
16
 
calculated five-year relative survival of 54% for a large series of MCC patients from the 
United States, whereas other studies have estimated relative and cause-specific survival rates 
of 62% and 64% after 5 years in the Netherlands
30
 and Western Australia
15
, respectively.  
While these latter results are similar to our estimate for cause-specific survival, they are 
substantially higher than the relative survival rate in Queensland.     
 
In most instances, relative survival closely resembles cause-specific survival estimates, as 
they are designed to measure the same outcome of net survival.  One situation where this 
does not hold true is when the underlying mortality in the cohort is substantially different to 
that in the general population after accounting for the disease of interest.
39
  This could 
possibly explain why there was a large disparity between the two measures in our study, 
particularly given that more than half of the deaths within the MCC cohort were due to other 
causes.  Even so, it is still not clear why our estimate of relative survival was substantially 
lower than some of the other published results, although the higher proportion of cases with 
metastases at diagnosis in the Queensland cohort may have contributed to these differences to 
some extent.   
 
Several prognostic factors for MCCs have been identified by other researchers, including sex, 
site, immune suppression, histopathologic type, growth pattern, and most importantly, the 
extent of disease at presentation (variously characterised by stage, tumour size or depth and 
lymphovascular invasion).
5,15,19,40
 The influence of MCPyV on survival is controversial,
10,11
 
but we were not able to measure this in the current study. We found significant differences in 
the risk of mortality by age, body site and stage at diagnosis after multivariate analysis.  One 
notable difference was that MCCs on the head and neck have been previously associated with 
a poorer prognosis,
5
 which is the opposite of what occurred in Queensland.  The reasons for 
this are not evident.     
 
  Most previous studies on Merkel cell carcinoma have involved small samples of less than 
200 patients.  Therefore, the main strengths of our work were the larger size of the cohort 
combined with the fact that it represented all cases diagnosed in Queensland, and so was not 
subject to some of the selection biases that can result from a hospital-based series of patients.  
Another advantage was the supplementation of standard registry data items with information 
from histopathology reports.   
 
Only 1% of cases in our data were documented as being immunosuppressed, compared to 6% 
in a population-based MCC cohort from Western Australia.
15
  Information about 
immunosuppression status was not routinely reported in Queensland, so our result was 
probably an underestimate of the true proportion.  Unfortunately, the small number of 
immunosuppressed cases also meant that we were unable to assess survival for this subgroup. 
 
While every effort was made to verify legitimate MCC cases, we did not have access to 
stored biological material (such as specimens and tissue blocks) to assist with this process.  
While immunohistochemistry results other than CK20
41
 were available to confirm the 
diagnosis in approximately 80% of the audited histopathology records, the audit revealed that 
up to 5% of the patients included in this study may have been over-diagnosed.  However, this 
is a conservatively high estimate, and is considered acceptable when taking into account the 
specific histopathologic diagnostic challenges when dealing with small round blue cell 
tumours of the skin.  Conversely, it is also possible that some cases of MCC were 
inadvertently excluded due to being incorrectly classified as another type of cancer, but it was 
not possible to confirm this.      
 
In conclusion, our results establish that the incidence rate of MCC is much higher in 
Queensland than anywhere else in the world.  The central factor behind this undesirable 
statistic appears to be exposure to UV radiation.  While the greater attention placed on 
melanoma may be warranted given its higher incidence, people diagnosed with MCC have 
greatly reduced survival expectations. In light of these findings, it is imperative that clinical 
practice guidelines for the diagnosis and management of MCC, similar to those that already 
exist for other countries,
42,43
 are developed and implemented within Australia as soon as 
possible.
7
  Public awareness campaigns are also required to alert people that melanoma is not 
the only lethal form of skin cancer.  In particular, timely medical opinion should be 
encouraged for the rapid appearance of a new lesion, with emphasis placed on the importance 
of people becoming familiar with what is normal for their own skin.  It is hoped that these 
steps will lead to better outcomes for MCC patients into the future. 
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Table 1.  Characteristics of persons diagnosed with Merkel cell carcinoma by sex, 
Queensland, 1993-2010 
 
 Males Females Persons 
Characteristic n Col % n Col % n Col % 
TOTAL 602 100.0 277 100.0 879 100.0 
Age group at diagnosis Chi-square = 6.16; df = 4; p = 0.187  
  0-39 6 1.0 1 0.4 7 0.8 
  40-59 59 9.8 18 6.5 77 8.8 
  60-69 118 19.6 47 17.0 165 18.8 
  70-79 204 33.9 94 33.9 298 33.9 
  80+ 215 35.7 117 42.2 332 37.8 
Body site Chi-square = 41.35; df = 5; p < 0.001  
  Face/Ears 228 37.9 79 28.5 307 35.0 
  Scalp/Neck 77 12.8 24 8.7 101 11.5 
  Trunk 47 7.8 25 9.0 72 8.2 
  Upper limbs/shoulders 75 12.5 44 15.9 119 13.5 
  Lower limbs 66 11.0 72 26.0 138 15.7 
  Not specified 109 18.1 33 11.9 142 16.2 
Remoteness of residence
a
 Chi-square = 5.60; df = 4; p = 0.231  
  Major city 337 56.0 157 56.7 494 56.2 
  Inner regional 146 24.3 58 20.9 204 23.2 
  Outer regional 89 14.8 40 14.4 129 14.7 
  Remote/very remote 28 4.7 18 6.5 46 5.2 
  Not stated 2 0.3 4 1.4 6 0.7 
Multiple primary cancers (all types) Chi-square = 5.57; df = 2; p = 0.062  
  No 370 61.5 192 69.3 562 63.9 
  Yes – previous years 155 25.7 53 19.1 208 23.7 
  Yes – same/subsequent years 77 12.8 32 11.6 109 12.4 
Stage at diagnosis
b
 Chi-square = 4.42; df = 4; p = 0.352  
  Stage I 295 49.0 143 51.6 438 49.8 
  Stage II 55 9.1 34 12.3 89 10.1 
  Stage III 71 11.8 31 11.2 102 11.6 
  Stage IV 101 16.8 35 12.6 136 15.5 
  Unknown 80 13.3 34 12.3 114 13.0 
Level of invasion
c
 Chi-square = 6.31; df = 2; p = 0.043  
  Dermis 141 23.4 87 31.4 228 25.9 
  Dermis/subcutaneous 243 40.4 101 36.5 344 39.1 
  Not stated 218 36.2 89 32.1 307 34.9 
Surgical margins Chi-square = 2.28; df = 2; p = 0.320  
  Satisfactory (clear) 278 46.2 143 51.6 421 47.9 
  Unsatisfactory (not clear) 123 20.4 52 18.8 175 19.9 
  Not stated 201 33.4 82 29.6 283 32.2 
Immune status
d
 Chi-square = 0.02; df = 1; p = 0.893  
  Known to be immune suppressed 8 1.3 4 1.4 12 1.4 
  Not known to be immune suppressed 594 98.7 273 98.6 867 98.6 
Abbreviations/symbols:  n = number of cases; df = degrees of freedom. 
Notes: a. Remoteness of residence based on the Australian Standard Geographical Classification Remoteness Areas.44 
 b. Stage at diagnosis defined according to the criteria set out by the American Joint Committee on Cancer.16 
 c. Dermis category may include epidermal involvement.  Dermis/subcutaneous category includes cases where the  
  tumour extended beyond the dermal layer. 
 d. Immune status was categorised as suppressed for persons who were known to be a transplant recipient, HIV  
  positive or who were reported to have another cause of immune suppression. 
 
  
Table 2.  Annual percentage change (APC)
a
 in the incidence rates
b
 of Merkel cell 
carcinoma by selected characteristics, Queensland, 1993-2010 
 
Characteristic n APC (95% CI)
c
 p-value 
TOTAL 879 +2.6 (+1.1,+4.1) 0.002 
Sex    
  Males 602 +2.5 (+0.9,+4.1) 0.004 
  Females 277 +2.1 (-0.7,+5.1) 0.132 
Age group at diagnosis    
  0-59 84 -1.4 (-5.8,+3.2) 0.515 
  60-69 165 +2.0 (-1.1,+5.1) 0.195 
  70-79 298 +2.3 (+0.1,+4.6) 0.039 
  80+ 332 +3.7 (+1.0,+6.4) 0.009 
Body site
d
    
  Head 408 +3.1 (+1.1,+5.2) 0.005 
  Other 329 +1.3 (-1.1,+3.8) 0.259 
  Not specified 142 +2.2 (-1.5,+6.1) 0.225 
Stage at diagnosis
e
    
  Stages I 438 +3.6 (+1.1,+6.2) 0.008 
  Stages II+ 327 +2.9 (+0.2,+5.6) 0.036 
  Unknown 114 -2.9 (-6.2,+0.5) 0.086 
Abbreviations:  APC = annual percentage change; 95% CI = 95% confidence interval. 
Notes: a. Calculated using JoinPoint regression. 
 b. Rates were directly age-standardised to the 2000 United States Standard Population.20 
 c. Trends shown in bold were statistically significant. 
 d. Head includes the face, ears, scalp and neck.  Other body site includes the trunk, upper limbs, shoulders and  
     lower limbs. 
 e. Stage at diagnosis defined according to the criteria set out by the American Joint Committee on Cancer.16 
  
Table 3.  Five-year relative survival
a
 and adjusted hazard ratios for Merkel cell 








Adjusted HR (95% 
CI) 
p 
TOTAL 489 41.3 (34.4-48.4)    
Sex Chi-square = 1.59; df = 1; p = 0.208 
  Males 338 38.2  (30.0-46.8) 1.00 g  
  Females 151 48.1 (35.5-60.4) 0.77 (0.51-1.16) 0.208 
Age group at diagnosis Chi-square = 29.03; df = 3; p < 0.001 
  0-59 47 56.5 (35.8-73.1) 0.75 (0.36-1.58) 0.454 
  60-69 95 59.9 (43.5-73.6) 1.00 g  
  70-79 165 43.2 (32.0-54.4) 1.42 (0.83-2.44) 0.201 
  80+ 182 24.6 (14.0-38.3) 3.00 (1.76-5.10) <0.001 
Body site Chi-square = 12.00; df = 5; p = 0.035 
  Face/ears 186 51.3 (38.5-64.0) 1.00 g  
  Scalp/neck 47 45.2 (19.9-73.2) 1.02 (0.52-2.00) 0.955 
  Trunk 41 24.8 (10.2-43.6) 2.19 (1.16-4.13) 0.016 
  Upper limbs/shoulders 63 38.1 (20.4-57.5) 1.40 (0.77-2.53) 0.271 
  Lower limbs 76 33.3 (20.0-48.3) 1.81 (1.08-3.00) 0.022 




  Major city 273 38.6 (29.7-48.1)  (c)  
  Inner regional 119 51.3 (35.5-67.0)  (c)  
  Other/Unknown 97 36.8 (23.6-50.9)  (c)  
Multiple primary cancers (all types) Chi-square = 4.06; df = 2; p = 0.131 
  No 316 46.2 (37.1-55.2) 1.00 g  
  Yes – previous years 122 29.8 (17.4-44.3) 1.50 (1.01-2.23) 0.045 
  Yes – same/subsequent years 51 37.0 (20.0-55.8) 1.22 (0.69-2.17) 0.500 
Stage at diagnosis
e
 Chi-square = 9.91; df = 4; p = 0.042 
  Stage I 266 48.8 (38.8-58.7) 1.00 g  
  Stage II 53 26.2 (8.9-50.1) 1.83 (1.06-3.15) 0.030 
  Stage III 53 41.4 (21.7-63.1) 1.55 (0.87-2.74) 0.135 
  Stage IV 70 25.4 (13.4-39.8) 2.29 (1.21-4.36) 0.011 




  Dermis 141 45.5 (31.5-59.9)  (c)  
  Subcutaneous 204 41.9 (31.7-52.5)  (c)  
  Not stated 144 37.2 (25.3-49.7)  (c)  
Surgical margins Chi-square = 3.77; df = 2; p = 0.152 
  Satisfactory (clear) 272 47.5 (37.7-57.3) 1.00 g  
  Unsatisfactory (not clear) 86 39.9 (24.1-57.1) 1.29 (0.81-2.04) 0.277 
  Not stated 131 30.1 (18.9-42.5) 1.68 (0.96-2.94) 0.068 
Abbreviations:  RS = relative survival;  HR = hazard ratio;  95% CI = 95% confidence interval. 
Notes: a. Survival calculated using the period method for persons who were at risk of mortality due to Merkel cell  
     carcinoma between 1 Jan 2006 to 31 Dec 2010. 
 b. The number of persons who were eligible to contribute to the 5-year relative survival calculations. 
 c. Remoteness of residence and level of invasion were excluded from the final multivariate Poisson model for  
     calculating the hazard ratios because the overall effect for these variables was p>0.25. 
 d. Remoteness of residence based on the Australian Standard Geographical Classification Remoteness Areas.44 
 e. Stage at diagnosis defined according to the criteria set out by the American Joint Committee on Cancer.16 
 f. Dermis category may include epidermal involvement.  Dermis/subcutaneous category includes cases where the  
     tumour extended beyond the dermal layer. 
 g. Reference category.  
Figure 1.  Incidence rate trends for Merkel cell carcinoma by sex, age group at 
diagnosis, body site and stage at diagnosis, Queensland, 1993-2010.  Trends calculated using 
JoinPoint regression, based on rates that were directly age-standardised to the 2000 United States Standard 
Population.20  Head includes the face, ears, scalp and neck.  Other body site includes the trunk, upper limbs, 
shoulders and lower limbs.  Stage at diagnosis defined according to the criteria set out by the American Joint 
Committee on Cancer.16 
 
Figure 2.  Unadjusted relative survival curves for Merkel cell carcinoma by sex, age 
group at diagnosis, body site and stage at diagnosis, Queensland, 2006-2010.  Survival 
calculated using the period method for persons who were at risk of mortality due to Merkel cell carcinoma 
between 1 Jan 2006 to 31 Dec 2010.  Stage at diagnosis defined according to the criteria set out by the American 
Joint Committee on Cancer.16 
 
 
